Phase 1 Trial Results Show Covaxin Has Tolerable Safety and Enhanced Immunity: Lancet Study | India News
NEW DELHI: India’s first indigenous COVID-19 vaccine, Covaxin, showed an enhanced immune response without serious side effects in participants enrolled in Phase 1 trials, according to results published in The Lancet Infectious Disease. Developed by Bharat Biotech in collaboration with the Indian Council for Medical Research (ICMR) and the National Institute of Virology (NIV), Pune,…
Read More